This WIREs title offers downloadable PowerPoint presentations of figures for non-profit,
educational use, provided the content is not modified and full credit is given to the author
and publication.
References 1 Barabasi, AL, Oltvai, ZN. Network biology: understanding the cell`s functional organization. Nat Rev Genet 2004, 5: 101–113.et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446: 153–158.et al. A census of human cancer genes. Nat Rev Cancer 2004, 4: 177–183.et al. Association between an oncogene and an anti‐oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 1988, 334: 124–129.et al. Association of p300 and CBP with simian virus 40 large T antigen. Mol Cell Biol 1996, 16: 3454–3464.et al. Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity. Cell 1987, 50: 1021–1029.et al. Viral oncoprotein‐induced mislocalization of select PDZ proteins disrupts tight junctions and causes polarity defects in epithelial cells. J Cell Sci 2005, 118: 4283–4293.et al. The adenovirus E4‐ORF4 splicing enhancer protein interacts with a subset of phosphorylated SR proteins. EMBO J 2001, 20: 864–871.et al. Regulation of p53 levels by the E1B 55‐kilodalton protein and E4orf6 in adenovirus‐infected cells. J Virol 1997, 71: 3788–3798.et al. The adenovirus early region 4 open reading frame 6/7 protein regulates the DNA binding activity of the cellular transcription factor, E2F, through a direct complex. Genes Dev 1989, 3: 1699–1710.et al. DP‐1: a cell cycle‐regulated and phosphorylated component of transcription factor DRTF1/E2F which is functionally important for recognition by pRb and the adenovirus E4 orf 6/7 protein. EMBO J 1994, 13: 3104–3114.et al. Antibodies specific for the human retinoblastoma protein identify a family of related polypeptides. Mol Cell Biol 1991, 11: 5792–5799.et al. Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain. Oncogene 1993, 8: 2561–2566.Jr, Beach, D, et al. A 60 kd cdc2‐associated polypeptide complexes with the E1A proteins in adenovirus‐infected cells. Cell 1989, 58: 981–990.et al. Direct interaction between adenovirus E1A protein and the TATA box binding transcription factor IID. Proc Natl Acad Sci U S A 1991, 88: 5124–5128.et al. Cell cycle regulation of histone H1 kinase activity associated with the adenoviral protein E1A. Science New York, N.Y 1991, 253: 1271–1275.et al. A region in the C‐terminus of adenovirus 2/5 E1a protein is required for association with a cellular phosphoprotein and important for the negative modulation of T24‐ras mediated transformation, tumorigenesis and metastasis. EMBO J 1993, 12: 469–478.et al. Adenovirus E1A proteins interact with the cellular YY1 transcription factor. J Virol 1995, 69: 1628–1636.et al. Repression of a matrix metalloprotease gene by E1A correlates with its ability to bind to cell type‐specific transcription factor AP‐2. Proc Natl Acad Sci U S A 1996, 93: 3088–3093.et al. Direct suppression of Stat1 function during adenoviral infection. Immunity 1998, 9: 871–880.et al. BS69, a novel adenovirus E1A‐associated protein that inhibits E1A transactivation. EMBO J 1995, 14: 3159–3169.et al. Regulation of the 26S proteasome by adenovirus E1A. EMBO J 2000, 19: 4759–4773.et al. The targeting of the proteasomal regulatory subunit S2 by adenovirus E1A causes inhibition of proteasomal activity and increased p53 expression. J Biol Chem 2004, 279: 25122–25133.et al. Binding of PKA‐RIIalpha to the Adenovirus E1A12S oncoprotein correlates with its nuclear translocation and an increase in PKA‐dependent promoter activity. Virology 2001, 285: 30–41.et al. RACK1 interacts with E1A and rescues E1A‐induced yeast growth inhibition and mammalian cell apoptosis. J Biol Chem 2001, 276: 27026–27033.et al. The p400 complex is an essential E1A transformation target. Cell 2001, 106: 297–307.et al. E1A physically interacts with RUNX3 and inhibits its transactivation activity. J Cell Biochem 2008, 105: 236–244.et al. mUBC9, a novel adenovirus E1A‐interacting protein that complements a yeast cell cycle defect. J Biol Chem 1996, 271: 25906–25911.et al. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53‐inducible and death‐promoting Bax protein. Genes Dev 1996, 10: 461–477.et al. Cloning of a bcl‐2 homologue by interaction with adenovirus E1B 19K. Nature 1995, 374: 731–733.et al. E1B 55‐kilodalton‐associated protein: a cellular protein with RNA‐binding activity implicated in nucleocytoplasmic transport of adenovirus and cellular mRNAs. J Virol 1998, 72: 7960–7971.et al. Binding of high‐risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A 1997, 94: 11612–11616.et al. The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J Virol 2007, 81: 4116–4129.et al. Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol Cell Biol 2002, 22: 5801–5812.et al. Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. J Biol Chem 2004, 279: 35664–35670.et al. Human papillomavirus E6‐induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase. Cancer Res 2002, 62: 3315–3321.et al. Interference of papillomavirus E6 protein with single‐strand break repair by interaction with XRCC1. EMBO J 2002, 21: 4741–4748.et al. PKN binds and phosphorylates human papillomavirus E6 oncoprotein. J Biol Chem 2000, 275: 14824–14830.et al. The human papilloma virus (HPV)‐18 E6 oncoprotein physically associates with Tyk2 and impairs Jak‐STAT activation by interferon‐alpha. Oncogene 1999, 18: 5727–5737.et al. BRCA1 interaction with human papillomavirus oncoproteins. J Biol Chem 2005, 280: 33165–33177.et al. Inhibition of CDK activity and PCNA‐dependent DNA replication by p21 is blocked by interaction with the HPV‐16 E7 oncoprotein. Genes Dev 1997, 11: 2090–2100.et al. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV‐18 E6 through ubiquitin mediated degradation. Oncogene 1996, 13: 265–273.et al. HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene 1993, 8: 195–202.et al. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J 1999, 18: 2449–2458.et al. Association of the human papillomavirus type 16 E7 oncoprotein with the 600‐kDa retinoblastoma protein‐associated factor, p600. Proc Natl Acad Sci U S A 2005, 102: 11492–11497.et al. Allosteric activation of acid alpha‐glucosidase by the human papillomavirus E7 protein. J Biol Chem 2000, 275: 9534–9541.et al. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci U S A 1999, 96: 1291–1296.et al. Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth‐inhibitory insulin‐like growth factor binding protein 3. Mol Cell Biol 2000, 20: 6483–6495.et al. Inactivation of interferon regulatory factor‐1 tumor suppressor protein by HPV E7 oncoprotein; implication for the E7‐mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 2000, 275: 6764–6769.et al. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988, 54: 275–283.et al. Simian virus 40 large T antigen targets the spindle assembly checkpoint protein Bub1. Proc Natl Acad Sci U S A 2004, 101: 947–952.et al. Interaction between T antigen and TEA domain of the factor TEF‐1 derepresses simian virus 40 late promoter in vitro: identification of T‐antigen domains important for transcription control. J Virol 1996, 70: 1203–1212.et al. SV40 T antigen interacts with Nbs1 to disrupt DNA replication control. Genes Dev 2004, 18: 1305–1316.et al. Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell 1990, 60: 167–176.et al. Cellular proteins that associate with the middle and small T antigens of polyomavirus. J Virol 1988, 62: 3934–3940.et al. Association of polyomavirus middle tumor antigen with 14‐3‐3 proteins. Science New York, NY 1994, 265: 535–537.et al. Transformation by polyoma virus middle T‐antigen involves the binding and tyrosine phosphorylation of Shc. Nature 1994, 367: 87–90.et al. Structural elements that regulate pp59c‐fyn catalytic activity, transforming potential, and ability to associate with polyomavirus middle‐T antigen. J Virol 1991, 65: 170–179.et al. Identification of a cell protein (FIP‐3) as a modulator of NF‐kappaB activity and as a target of an adenovirus inhibitor of tumor necrosis factor alpha‐induced apoptosis. Proc Natl Acad Sci U S A 1999, 96: 1042–1047.et al. Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication. EMBO J 2005, 24: 1211–1221.et al. Alterations of the PPP2R1B gene in human lung and colon cancer. Science New York, NY 1998, 282: 284–287.et al. The beta2‐microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. EMBO J 1983, 2: 239–243.et al. Adenovirus E3 14.7K protein functions in the absence of other adenovirus proteins to protect transfected cells from tumor necrosis factor cytolysis. J Virol 1991, 65: 2629–2639.et al. Forced degradation of Fas inhibits apoptosis in adenovirus‐infected cells. Nature 1998, 392: 726–730.et al. Inhibition of TRAIL‐induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins. J Virol 2001, 75: 8875–8887.et al. Somatic mutations of Fas (Apo‐1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scar. J Invest Dermatol 2000, 114: 122–126.et al. Rare loss‐of‐function mutation of a death receptor gene in head and neck cancer. Cancer Res 1998, 58: 3513–3518.et al. Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling. Proc Natl Acad Sci U S A 1996, 93: 15092–15096.et al. A generic protein purification method for protein complex characterization and proteome exploration. Nat Biotechnol 1999, 17: 1030–1032.et al. The tandem affinity purification (TAP) method: a general procedure of protein complex purification. Methods 2001, 24: 218–229.et al. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 2002, 415: 141–147.et al. Wilms tumor suppressor WTX negatively regulates WNT/beta‐catenin signaling. Science New York, NY 2007, 316: 1043–1046.et al. I‐DIRT, a general method for distinguishing between specific and nonspecific protein interactions. J Proteome Res 2005, 4: 1752–1756.et al. Global analysis of protein activities using proteome chips. Science New York, NY 2001, 293: 2101–2105.et al. Global analysis of protein phosphorylation in yeast. Nature 2005, 438: 679–684.et al. Ubiquitination screen using protein microarrays for comprehensive identification of Rsp5 substrates in yeast. Mol Syst Biol 2007, 3: 116.et al. Identification of HPV‐16 E7 peptides that are potent antagonists of E7 binding to the retinoblastoma suppressor protein. J Biol Chem 1990, 265: 12782–12785.et al. A fully integrated protein crystallization platform for small‐molecule drug discovery. J Struct Biol 2003, 142: 207–217.et al. Structural basis of PP2A inhibition by small t antigen. PLoS Biol 2007, 5: e202.et al. Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. Genes Dev 2002, 16: 583–593.et al. Restoration of the tumor suppressor function to mutant p53 by a low‐molecular‐weight compound. Nat Med 2002, 8: 282–288.et al. Modelling Myc inhibition as a cancer therapy. Nature 2008, 455: 679–683.et al. Epigenetic reprogramming by adenovirus e1a. Science New York, NY 2008, 321: 1086–1088.et al. Sequence complexity of disordered protein. Proteins 2001, 42: 38–48.
.jpg)
.jpg)
.jpg)
.jpg)
